Xenon Pharmaceuticals Participation at CNS Therapeutics Conference
Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a notable name in neuroscience-focused biopharmaceuticals, has recently announced its involvement in the highly anticipated BofA Securities 2024 CNS Therapeutics Virtual Conference. This event is scheduled for October 7, 2024, and is set to showcase critical developments and innovations in the field of central nervous system therapeutics.
Key Presentation Details
The conference will include a fireside chat featuring Xenon Pharmaceuticals, where executives will discuss the company’s pipeline and advancements aimed at significantly enhancing patient care. The presentation is particularly noteworthy for those interested in neurological and psychiatric disorders.
Date and Time Highlights
The fireside chat is scheduled for Monday, October 7, 2024, at 11:40 am Eastern Time. Interested participants can access the event through a live webcast available on the Investors section of Xenon's official website. This platform ensures that both attendees and stakeholders can engage with the company's insights and progress.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is driven by a mission to discover, develop, and distribute innovative therapeutics that improve the lives of individuals facing complex neurological challenges. The company is focused on addressing significant unmet medical needs, particularly in areas like epilepsy and depression.
Innovative Product Pipeline
One of Xenon’s leading candidates is Azetukalner, a groundbreaking Kv7 channel opener. This product stands out as a clinically validated potassium channel modulator and is currently in late-stage clinical development for multiple indications. Through such innovations, Xenon is paving the way for new treatment modalities that could transform patient outcomes in neurology.
Company Commitment
Xenon Pharmaceuticals remains committed to advancing research and development efforts aimed at unveiling novel therapeutic options for patients enduring neurological disorders. Their innovative spirit continues to drive various projects that seek to improve patient care and healing in the realm of neuroscience.
Company Leadership and Impact
The leadership at Xenon is comprised of experienced professionals dedicated to steering the company toward breakthrough achievements in therapeutic interventions. As the company progresses, it aims to deliver solutions that meet the urgent requests of healthcare providers and patients alike.
Contact Information
For those wanting to connect with Xenon’s team, contact details are as follows: For investors, reach out to Chad Fugere, Vice President of Investor Relations, at (857) 675-7275 or via email. Media inquiries can be directed to Colleen Alabiso, Senior Vice President of Corporate Affairs, at (617) 671-9238.
Frequently Asked Questions
What is the focus of Xenon Pharmaceuticals?
Xenon Pharmaceuticals specializes in developing innovative therapeutics for neurological and psychiatric disorders.
When is Xenon Pharmaceuticals participating in the CNS Therapeutics conference?
The company will present on October 7, 2024, at the BofA Securities Virtual Conference.
What is Azetukalner?
Azetukalner is Xenon's lead Kv7 channel opener, currently in late-stage clinical development for multiple indications.
How can I watch the Xenon presentation?
The presentation will be available via live webcast on the Investors section of Xenon’s website.
Who should I contact for investor relations at Xenon?
Chad Fugere is the appropriate contact for investor inquiries at Xenon Pharmaceuticals.